JMP Securities Initiates Astria Therapeutics (ATXS) at Market Outperform

JMP Securities analyst Jonathan Wolleben initiated Astria Therapeutics (NASDAQ: ATXS) at Market Outperform with a price target of $26.00.

The analyst commented, “Astria is using its half-life extension technology to develop long-acting mAbs targeting derisked targets in large, proven markets. Its lead candidate, navenibart, is starting Phase 3 testing to prevent hereditary angioedema (HAE) attacks, while its second candidate, STAR-0310, is starting clinical testing for atopic dermatitis.”

For an analyst ratings summary and ratings history on Astria Therapeutics click here. For more ratings news on Astria Therapeutics click here.

Shares of Astria Therapeutics closed at $7.49 yesterday.

You May Also Be Interested In

• Bernstein SocGen Group Starts Terawulf Inc. (WULF) at Outperform
• Goldman Sachs Upgrades Plains GP Holdings, L.P (PAGP) to Neutral
• BTIG Upgrades Medtronic, Inc. (MDT) to Buy